This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Parkinson Disease
and you are
over 30
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies.

Provided treatments

  • Drug: Isradipine CR 5mg
  • Drug: Isradipine CR 10mg
  • Drug: Isradipine CR 20mg
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT00909545. The sponsor of the trial is Northwestern University and it is looking for 99 volunteers for the current phase.
Official trial title:
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease